← All trials
NCT05660213
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2023
- Primary completion
- Jan 1, 2025
- Completion date
- Mar 1, 2025
- First posted
- Dec 21, 2022
- Last posted
- Dec 22, 2022
- Enrollment
- 60
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Fudan UniversityLead sponsor
- Fudan UniversityReponsible party - principal investigator
- Huazhong University of Science and TechnologyCollaborator
- LinkDoc Technology (Beijing) Co. Ltd.Collaborator
- Fudan UniversitySponsor investigator
- Fudan UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.